Summary
The episode works through how to identify the drug, the category system and the setting on which a claim about psychedelics rests, beginning with a storefront statement that borrows evidence from trials of MDMA-assisted therapy. Sarah and Kiffer count the hours of supervised sessions in a published MDMA protocol to show that such trials estimate the added effect of a drug within a course of therapy, and they set out the lawful routes in Canada for therapy with psilocybin or MDMA as of October 2026, as general information about the law. A hypothetical calculation shows why the share of written user reports that describe a challenging experience can misstate how often such experiences occur, however large the collection becomes. The hosts compare the mental health figures of the Canadian Substance Use Survey for 2023 and 2025 and apply the six-item checklist to a 2026 pilot randomized trial of psilocybin for smoking cessation, in which Sarah separates randomization from blinding. They close by debating whether company-reported phase 3 results for psilocybin in treatment-resistant depression reflect hype or a modest benefit that risks being dismissed.